APA (7th ed.) Citation

YJ, M., N, M., T, D., S, L., K, S., S, B., . . . JK, J. (2026). FAP adipogenesis drives early spinal muscle loss in dysferlinopathy and reveals a therapeutic target. EMBO molecular medicine, 18(10), 4034. https://doi.org/10.1038/s44321-026-00514-5

Chicago Style (17th ed.) Citation

YJ, Moon, et al. "FAP Adipogenesis Drives Early Spinal Muscle Loss in Dysferlinopathy and Reveals a Therapeutic Target." EMBO Molecular Medicine 18, no. 10 (2026): 4034. https://doi.org/10.1038/s44321-026-00514-5.

MLA (9th ed.) Citation

YJ, Moon, et al. "FAP Adipogenesis Drives Early Spinal Muscle Loss in Dysferlinopathy and Reveals a Therapeutic Target." EMBO Molecular Medicine, vol. 18, no. 10, 2026, p. 4034, https://doi.org/10.1038/s44321-026-00514-5.